Table 3.
Event | N (%) | |
---|---|---|
Cause of death | Refractory respiratory failure | 7/15 (46.6) |
Cerebrovascular event | 1/15 (6.6) | |
Cardiovascular event | 1/15 (6.6) | |
Sepsis with septic shock | 6/15 (40) | |
Infections | Secondary bacterial infections | 8/41 (19.5) |
Mucormycosis | 2/41 (4.8) | |
Aspergillosis | 3/41 (7.3) | |
>1 infection | 5/41 (12.2) | |
Adverse events attributed to tofacitinib | Pulmonary thrombosis | 1/41 (2.4) |